We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Prothrombotic effect of erythropoietin in dialysis patients.
- Authors
Taylor, J. E.; McLaren, M.; Henderson, S.; Belch, J. J. F.; Stewart, W. K.
- Abstract
Thrombin-antithrombin III complex concentrations (TAT-III) were measured in 18 anaemic haemodialysis patients treated with erythropoietin (Epo) and in four haemodialysis patients treated with i.v. iron dextran. There was a significant early increase in thrombinantithrombin III in erythropoietin-treated patients which appeared to be independent of the response to erythropoietin (Epo responders (n= 14), pretreatment TAT-III median (range) 3.10 (2.70–9.10) μg/1; maximum TAT-III 19.48 (11.18–60.00) μg/1, /<0.001, Wilcoxon; Epo non-responders (n = 4), pretreatment TAT-III 3.15 (2.90–4.50) μg/1, maximum TAT-III 16.00 (10.31–36.12) μg/1, /P<0.001). This was not seen in iron-dextran-treated patients (Pretreatment TAT-III 2.05 (1.90–9.48) μg/1, maximum TAT-III 5.60 (2.10–14.50) ug/1). The change was not related to haemoglobin, erythropoietin dose, or method of administration, and was transient in nature, thrombin- antithrombin III returning to pretreatment values after approximately 6 months in all patients (Epo responders 6.0(4.0–9.0) months, TAT-III 2.47 (1.30–9.23) μg/1; Epo non-responders 7.0 months, TAT-III 5.04 (2.10–7.00) μug/1). Increased thrombin-antithrombin III complex may reflect an effect of erythropoietin on microcirculatory factors, which could be relevant to the occurrence of adverse events during treatment
- Publication
Nephrology Dialysis Transplantation, 1992, Vol 7, Issue 3, p235
- ISSN
0931-0509
- Publication type
Article